Mobile App

Google Play Apple Store
Conversations in Oncology: Updates in the Treatment of Early Non-Small Cell Lung Cancer
Certified AMA/ANCC Activity
With the recent approval of atezolizumab and osimertinib, and several ongoing trials, it has become clear that immunotherapy and targeted approaches are gaining ground in the adjuvant and neoadjuvant setting of early-stage non-small cell lung cancer (NSCLC). Considering the continual updates from clinical trials in this space, it is pivotal that healthcare professionals are familiar with the practical considerations to safely integrate this recent progress.

This activity will highlight the practice-changing updates in adjuvant and neoadjuvant approaches in early-stage NSCLC, to enable safe and effective implementation into clinical practice through expert-guided discussions with Drs. Julie Brahmer, Jamie Chaft and Stephen Liu.
Review the video(s) to claim AMA/ANCC credit after completion of the brief Post-Test/Evaluation(s).




Julie R. Brahmer, MD, MSc Julie R. Brahmer, MD, MSc
Co-Director, Division of Upper Aerodigestive Cancer Program
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Jamie Chaft, MD Jamie Chaft, MD
Associate Attending Physician
Memorial Sloan Kettering Cancer Center
Associate Professor
Weill Cornell Medical College
Stephen Liu, MD Stephen Liu, MD
Associate Professor of Medicine
Director of Thoracic Oncology
Director of Developmental Therapeutics
Lombardi Comprehensive Cancer Center
Georgetown University

20

Supported by an independent educational grant from Merck Sharp & Dohme, LLC.


Launch Date: September 12, 2022

Expiration Date: August 31, 2023

August 31, 2023
Mini Module
7439
EarlyLungCancer_WebBanner(1150).gif
Hematology-Oncology